Oxford Astrazeneca
-
{
- All
- News
- Videos
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
Covishield Comprises Over 90% Of 12.76 Crore Covid Vaccines Given So Far: Government Data
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday.
-
Growing Evidence On Oxford Shot Should Guide Other Countries, Vaccine Chief Says
Real-world data on the effectiveness of Oxford and AstraZeneca's COVID-19 vaccine in older people from its rollout in Britain should help inform decision making in other countries, Oxford Vaccine Group Director Andrew Pollard said on Tuesday.
-
Oxford Vaccine, Approved By UK, Easier To Store, Cheaper Than Others
A coronavirus vaccine developed by drug firm AstraZeneca and Oxford University has been approved for use in Britain, the government said Wednesday, adding the mass rollout will start on January 4.
-
UK Medicine Regulator To Assess Best Dose For Oxford COVID-19 Vaccine
Britain's medical regulator will examine all the data from trials of the COVID-19 vaccine developed by Oxford and AstraZeneca, including which dosing regimen is best to use, the regulator's chief executive said on Wednesday.
-
AstraZeneca-Oxford First To Publish Final-Stage Vaccine Trial Results
Oxford University and AstraZeneca on Tuesday became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle in the global race to produce safe and effective drugs for the coronavirus.
-
"Half-Dose Trial Finding Intriguing Result": Oxford Vaccine Chief
The Oxford/AstraZeneca COVID-19 vaccine candidate's late-stage trial results are "intriguing" and more work needs to be done on the finding that an initial half dose of the shot offers more protection, Oxford's vaccine chief said on Monday.
-
Oxford COVID-19 Vaccine Trials Produce Robust Immune Response In Elderly: Report
The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
-
COVID-19 Vaccine Trial Will Continue, Says Oxford After Volunteer Dies
Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
Covishield Comprises Over 90% Of 12.76 Crore Covid Vaccines Given So Far: Government Data
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday.
-
Growing Evidence On Oxford Shot Should Guide Other Countries, Vaccine Chief Says
Real-world data on the effectiveness of Oxford and AstraZeneca's COVID-19 vaccine in older people from its rollout in Britain should help inform decision making in other countries, Oxford Vaccine Group Director Andrew Pollard said on Tuesday.
-
Oxford Vaccine, Approved By UK, Easier To Store, Cheaper Than Others
A coronavirus vaccine developed by drug firm AstraZeneca and Oxford University has been approved for use in Britain, the government said Wednesday, adding the mass rollout will start on January 4.
-
UK Medicine Regulator To Assess Best Dose For Oxford COVID-19 Vaccine
Britain's medical regulator will examine all the data from trials of the COVID-19 vaccine developed by Oxford and AstraZeneca, including which dosing regimen is best to use, the regulator's chief executive said on Wednesday.
-
AstraZeneca-Oxford First To Publish Final-Stage Vaccine Trial Results
Oxford University and AstraZeneca on Tuesday became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle in the global race to produce safe and effective drugs for the coronavirus.
-
"Half-Dose Trial Finding Intriguing Result": Oxford Vaccine Chief
The Oxford/AstraZeneca COVID-19 vaccine candidate's late-stage trial results are "intriguing" and more work needs to be done on the finding that an initial half dose of the shot offers more protection, Oxford's vaccine chief said on Monday.
-
Oxford COVID-19 Vaccine Trials Produce Robust Immune Response In Elderly: Report
The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
-
COVID-19 Vaccine Trial Will Continue, Says Oxford After Volunteer Dies
Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.
